Mechanism of Action of Suvorexant
Suvorexant works by blocking orexin receptors (OX1R and OX2R), which suppresses the wake-promoting signals in the brain, thereby facilitating sleep. 1
How Suvorexant Works
Suvorexant is a dual orexin receptor antagonist that specifically targets the orexin neuropeptide signaling system, which plays a critical role in maintaining wakefulness 1, 2. The drug binds with high affinity to both orexin receptor subtypes:
- OX1R (Ki = 0.55 nM)
- OX2R (Ki = 0.35 nM) 1
By blocking these receptors, suvorexant prevents the wake-promoting neuropeptides orexin A and orexin B from binding to their receptors, effectively suppressing the brain's "wake drive" 1. This represents a fundamentally different approach from traditional hypnotics like benzodiazepines or Z-drugs, which enhance GABAergic inhibition.
Clinical Significance of This Mechanism
The orexin antagonism mechanism preserves natural sleep architecture, unlike traditional sedative-hypnotics that alter sleep profiles 3, 4. This means suvorexant prolongs the time spent in each natural sleep state rather than artificially inducing sedation 3.
This unique mechanism explains why:
- Suvorexant primarily improves sleep maintenance (wake after sleep onset) rather than just sleep onset 5
- The drug has a relatively benign side effect profile compared to traditional hypnotics 5
- There is minimal risk of physical dependence with chronic use 6, 4
- Daytime somnolence is typically mild to moderate when it occurs 5
Important Mechanistic Considerations
The orexin receptor antagonism may also underlie potential adverse effects such as narcolepsy-like symptoms or cataplexy 1. This is because genetic mutations in the orexin system in animals result in hereditary narcolepsy, and loss of orexin neurons has been documented in humans with narcolepsy 1. However, in clinical trials, there was no evidence of emergence of narcolepsy symptoms at FDA-approved doses 5.
The drug is primarily metabolized by CYP3A (with minor contribution from CYP2C19), has a half-life of approximately 12 hours, and reaches peak concentrations at a median of 2 hours after administration 1.